For Sale: Repros Suffers An FDA Clinical Hold And Potential NASDAQ Delisting
FDA asks Repros to determine whether a lower dose of Proellex will lessen liver toxicity risks, but the company is strapped for cash.
FDA asks Repros to determine whether a lower dose of Proellex will lessen liver toxicity risks, but the company is strapped for cash.